Satellos Bioscience, Inc.

– The first healthy volunteer has been dosed in the first component of the Phase 1 study – Initial safety and pharmacokinetic data expected in Q4 2024 – Initiation of the second component of the Phase 1 study, in adult DMD patients, expected in Q1 2025 TORONTO, Canada I September 18, 2024 I Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant has been dosed in a Phase 1 clinical study of SAT-3247. SAT-3247 is a novel, oral small molecule drug targeting AAK1 that is designed to regenerate skeletal muscle in Duchenne muscular dystrophy (DMD or Duchenne) and other degenerative or injury conditions involving muscle tissue. “We are excited to announce the dosing of the first participants in our Phase 1 clinical trial of SAT-3247, transforming Satellos into a clinical stage company. This milestone marks a significant step in our commitment to developing innovative therapies to regenerate muscle for those living with Duchenne and other muscle degenerative or injury conditions,” said Frank Gleeson, Co-founder and CEO, Satellos. “We look forward to advancing this trial and gaining valuable insights into the safety and pharmacological profile of SAT-3247.” The Phase 1 clinical trial will comprise two components. In the first component, 72 healthy volunteers will be enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design study to assess the safety and pharmacokinetic properties of SAT-3247. Participants will be randomized across five single-ascending dose (SAD) cohorts, four multiple-ascending dose (MAD) cohorts, and one food effect dose cohort. In the second component, expected to begin in late Q4 2024, 10 adult volunteers with genetically confirmed DMD will be enrolled in a 28-day, open-label, single dose cohort to assess safety and pharmacokinetic properties in patients and explore potential pharmacodynamic markers. About SAT-3247 SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD or Duchenne) and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy is an inherited disease caused by mutations in the dystrophin gene that no longer allow the dystrophin protein to function properly. Consequently, as discovered by Satellos, muscle repair and regeneration are impaired. Satellos designed SAT-3247 to restore the process of muscle repair and regeneration by regulating a dystrophin-independent pathway with the goal of increasing muscle function. SAT-3247 is intended to work as a standalone therapeutic without regard to a patient’s genetic mutation or ambulatory status. Our approach has the potential to complement approaches designed to restore dystrophin production. About Satellos Bioscience Inc. Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX TM , to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com . SOURCE: Satellos Bioscience

Inaugural Fundraising Event Coordinated by Nick and Jenner Jensen Raises Awareness, Vital Funds for Duchenne Muscular Dystrophy Research WASHINGTON, Aug. 22, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is thrilled to announce the success of the inaugural Swing Fore the Future golf tournament, which took place on August 19th, 2024, at the prestigious Army Navy Country Club in Arlington, Virginia. The event, coordinated by former Washington Capitals defenseman Nick Jensen and his wife, Jenner, brought together several current Capitals and National Hockey League players and alumni, passionate supporters, families, and community leaders to raise more than $170,000 to support research and advocacy in the fight to end Duchenne. Continue Reading Swing Fore The Future 2024 | Photo Credit: Jess Rapfogel Swing Fore The Future 2024 | Photo Credit: Jess Rapfogel Swing Fore The Future 2024 | Photo Credit: Jess Rapfogel Participants included Capitals players John Carlson, Nic Dowd, Pierre-Luc Dubois, Connor McMichael, T.J. Oshie, Matt Roy, Dylan Strome, Logan Thompson, and Trevor van Riemsdyk; former Capitals players Nicolas Aube-Kubel, Nick Jensen, Anthony Mantha, and Conor Sheary; Capitals alumni Karl Alzner and Braden Holtby; Hershey Bears player Matthew Strome and former Nationals player Ryan Zimmerman. Monumental Sports Network's Alexa Landestoy and Tarik El-Bashir also participated, as well as Capitals anthem singer Bob McDonald. This year's tournament saw more than 115 participants, including Capitals and NHL players and alumni and other members of the professional hockey community, local business leaders, and dedicated supporters, all united by a common goal: to end Duchenne. The event featured an 18-hole scramble, a meet and greet with players, special contests, raffle opportunities, a virtual auction, and a dinner with participating players. "We are incredibly grateful for the overwhelming support we received at this year's Swing Fore the Future event," said Nicole Herring, PPMD's Vice President of Development and Community Engagement. "The tournament was not only a fundraising success but also an opportunity to raise awareness about Duchenne and our fight for every future. The funds raised will directly support PPMD's and the Capitals' shared vision of finding therapeutic options for all individuals with Duchenne, regardless of their genetic mutation." PPMD extends its heartfelt thanks to the Jensen family, the Capitals, the Monumental Sports & Entertainment Foundation, event sponsors Kraemer Charity Volleyball Tournament, Satellos Bioscience, Active Play, Hunt Family Foundation, and JSONART, hole and beverage cart sponsors, volunteers, and participants who made the inaugural Swing Fore the Future golf tournament an outstanding success. The funds raised will play a pivotal role in advancing our efforts to improve the quality of life for all individuals living with Duchenne and their families. ABOUT PARENT PROJECT MUSCULAR DYSTROPHY Duchenne is a genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne. We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won eight FDA approvals. Everything we do—and everything we have done since our founding in 1994—helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne at EndDuchenne.org. Follow PPMD on Facebook, Twitter, Instagram, and YouTube. Photo Credit: Jess Rapfogel SOURCE Parent Project Muscular Dystrophy (PPMD)

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 TORONTO, Canada I August 19, 2024 I Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced acceptance of a clinical research proposal to a Human Research Ethics Committee (HREC) in Australia seeking regulatory authorization under their Therapeutic Goods Administration’s (TGA’s) Clinical Trial Notification (CTN) scheme to conduct a first-in-human Phase 1 clinical trial of SAT-3247. “Receiving clearance to commence clinical development of SAT-3247 represents a watershed moment for Satellos as we advance the first small molecule drug of its kind with the potential to restore the innate muscle regeneration and repair process that we discovered is dysfunctional in people living with Duchenne,” said Frank Gleeson, CEO and Co-founder of Satellos. “We are excited to be advancing SAT-3247 into first-in-human studies and begin this next important chapter for Satellos in developing an oral pill which we believe has the potential to be disease modifying.” The Phase 1 clinical trial will comprise two components. In the first component of the study, 72 healthy volunteers will be enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design to assess the safety and pharmacokinetic properties of SAT-3247. Participants will be randomized across 5 single-ascending dose (SAD) cohorts, 4 multiple-ascending dose (MAD) cohorts and one food effect (FE) dose cohort. In the second component of the study, 10 adult volunteers with genetically confirmed DMD will be enrolled in a 28-day, open-label dose cohort to compare safety and pharmacokinetic properties with the healthy volunteer data and explore pharmacodynamic markers. About SAT-3247 SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD of Duchenne) and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy is an inherited disease caused by mutations in the dystrophin gene that no longer allow the dystrophin protein to function properly. Consequently, as discovered by Satellos, muscle repair and regeneration are impaired. Satellos designed SAT-3247 to restore the process of muscle repair and regeneration by regulating a dystrophin-independent pathway with the goal of increasing muscle function. SAT-3247 is intended to work as a standalone therapeutic without regard to a patient’s genetic mutation or ambulatory status. Our approach has the potential to complement approaches designed to restore dystrophin production. About Satellos Bioscience Inc. Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX™, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com . SOURCE: Sattelos Bioscience